PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.72%
EBIT growth above 1.5x AVXL's 1.12%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
-21.99%
Negative operating income growth while AVXL is at 1.12%. Joel Greenblatt would press for urgent turnaround measures.
32.68%
Net income growth 1.25-1.5x AVXL's 26.17%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
32.51%
EPS growth 1.25-1.5x AVXL's 25.00%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
32.51%
Diluted EPS growth 1.25-1.5x AVXL's 25.00%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-20.05%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-102666.73%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-29000.87%
Negative 5Y OCF/share CAGR while AVXL is at 46.50%. Joel Greenblatt would question the firm’s operational model or cost structure.
0.57%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
-765363.95%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-27613.67%
Negative 5Y net income/share CAGR while AVXL is 62.57%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-208.91%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
82516.86%
10Y equity/share CAGR above 1.5x AVXL's 5007.93%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
5226.69%
5Y equity/share CAGR above 1.5x AVXL's 2291.33%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
1660.30%
3Y equity/share CAGR above 1.5x AVXL's 176.83%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.20%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.72%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-32.96%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
44.99%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-4.08%
We cut SG&A while AVXL invests at 19.92%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.